Fulcrum Therapeutics, Inc.
For the period ended Dec 31, 2025. Filed Feb 24, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 24, 2026
FULC$3.720.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations and Comprehensive Loss
(In thousands, except per share data)
| Year EndedDecember 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Collaboration revenue | — | 80,000 |
| Operating expenses: | ||
| Research and development | 56,103 | 63,386 |
| General and administrative | 28,666 | 36,448 |
| Restructuring expenses | — | 2,063 |
| Total operating expenses | 84,769 | 101,897 |
| Loss from operations | (84,769) | (21,897) |
| Other income, net | 9,889 | 12,172 |
| Net loss | $(74,880) | $(9,725) |
| Net loss per share, basic and diluted | $(1.18) | $(0.16) |
| Weighted-average common shares outstanding, basic and diluted | 63,355 | 61,984 |
| Comprehensive loss: | ||
| Net loss | $(74,880) | $(9,725) |
| Other comprehensive gain: | ||
| Unrealized gain on marketable securities | 44 | 266 |
| Total other comprehensive gain | 44 | 266 |
| Comprehensive loss | $(74,836) | $(9,459) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.